PHASE II: DOXIL CYCLOPHOSPHAMIDE,VINCRISTINE & PREDNISONE:AIDS SYSTEMIC LYMPHOMA

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。使用脂质体包封的药物治疗是一种相对较新的药物递送方式，似乎可以提高用于治疗癌症的药物的疗效和耐受性。Doxil是一种以这种方式递送的阿霉素制剂。本研究比较了Doxil在艾滋病相关系统性淋巴瘤患者中的疗效和耐受性，以及传统的以阿霉素为基础的化疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Drug therapy using liposomal encapsulation is a relatively new way of drug delivery that appears to enhance efficacy and tolerability of medications used to treat cancer. Doxil is a Doxorubicin formulation delivered this way. This study compares the efficacy and tolerability of Doxil in patients with Aids related systemic lymphoma with conventional doxorubicin-based chemotherapy.